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Abstract 
Polymorphisms in genes involved in folate metabolism may modulate the risk of colorectal 
cancer (CRC), but data from published studies are conflicting. The current meta-analysis was 
performed to address a more accurate estimation. A total of 41 (17,552 cases and 26,238 
controls), 24(8,263 cases and 12,033 controls), 12(3,758 cases and 5,646 controls), and 13 
(5,511 cases and 7,265 controls) studies were finally included for the association between 
methylenetetrahydrofolate reductase (MTHFR) C677T and A1289C, methione synthase reductase 
(MTRR) A66G, methionine synthase (MTR) A2756G polymorphisms and the risk of CRC, re-
spectively. The data showed that the MTHFR 677T allele was significantly associated with 
reduced risk of CRC (OR = 0.93, 95%CI 0.90-0.96), while the MTRR 66G allele was signifi-
cantly associated with increased risk of CRC (OR = 1.11, 95%CI 1.01-1.18). Sub-group 
analysis by ethnicity revealed that MTHFR C677T polymorphism was significantly associated 
with reduced risk of CRC in Asians (OR = 0.80, 95%CI 0.72-0.89) and Caucasians (OR = 0.84, 
95%CI 0.76-0.93) in recessive genetic model, while the MTRR 66GG genotype was found to 
significantly increase the risk of CRC in Caucasians (GG vs. AA: OR = 1.18, 95%CI 1.03-1.36). 
No significant association was found between MTHFR A1298C and MTR A2756G polymor-
phisms and the risk of CRC. Cumulative meta-analysis showed no particular time trend ex-
isted in the summary estimate. Probability of publication bias was low across all comparisons 
illustrated by the funnel plots and Egger’s test. Collectively, this meta-analysis suggested that 
MTHFR 677T allele might provide protection against CRC in worldwide populations, while 
MTRR 66G allele might increase the risk of CRC in Caucasians. Since potential confounders 
could not be ruled out completely, further studies were needed to confirm these results. 
Key words: Colorectal cancer; Methylenetetrahydrofolate reductase; Methione synthase reductase; 
Methionine synthase; Folate. 
Introduction 
Folate is critical to one-carbon metabolism, act-
ing  as  a  coenzyme  in  nucleotide  synthesis  and  the 
methylation of DNA, histones, and other proteins [1]. 
Accumulating evidence supports the important roles 
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of  folate  in  the  etiology  of  colorectal  cancer  (CRC). 
Methylenetetrahydrofolate  reductase  (MTHFR),  me-
thionine synthase (MTR), and methione synthase re-
ductase (MTRR) are key enzymes involved in folate 
metabolism, and play essential roles in DNA synthe-
sis,  repair,  and  methylation.  The  abnormalities  in 
these  processes  have  been  consistently  observed  in 
CRC patients, and are implicated in the pathogenesis 
of CRC [2].  
MTHFR  could  convert  5,10-methylenete-
trahydrofolate  (5,10-MTHF),  the  major  intracellular 
form of folate, to 5-methyltetrahydrofolate (5-MTHF), 
the major circulatory form of folate in the body (Fig.1) 
[3]. The 5-MTHF donates a methyl group to homo-
cysteine in the generation of methionine, which then 
converts  to  S-adenosylmethionine  (SAM),  the  uni-
versal methyl-group donor involved in  methylation 
reaction  including  DNA  methylation  [3,  4].  The 
methylation  of  homocysteine  to  methionine  is  cata-
lyzed  by  MTR  using  vitamin  B12  as  a  cofactor,  in 
which the MTR may become inactivated due to the 
oxidation of vitamin B12 cofactor. MTRR could cata-
lyze reductive methylation of vitamin B12 by using 
SAM as a methyl donor, leading to the activation of 
MTR [5, 6].  
Two common functional polymorphisms in the 
MTHFR  gene,  C677T  (rs1801133)  and  A1298C 
(rs1801131),  have  been  reported.  The  C677T  poly-
morphism  in  exon  4  of  MTHFR  gene  leads  to  the 
amino acid substitution of alanine by valine at codon 
222  (A222V)  which  could  cause  a  thermolabile  en-
zyme with lower activity [7]. Homozygotes TT have 
approximately  30%  of  normal  enzyme  activity, 
whereas heterozygotes CT have approximately 60% of 
the  normal  enzyme  activity,  hence  they  tend  to  ac-
cumulate 5,10-methylene-THF displacing the reaction 
towards the DNA synthesis at the expense of the pool 
of  methyl  donors  [8].  Another  MTHFR  polymor-
phism, A1298C polymorphism (rs1801131) in exon 7, 
could result in the substitution of glutamate by ala-
nine [9]. This polymorphism could lead to a decrease 
of 40% in enzyme activity of the variant genotype [10]. 
MTR  A2756G  (rs1805087)  gene  polymorphism  was 
initially thought to be associated with lower enzyme 
activity, leading to homocysteine elevation and DNA 
hypomethylation [11]. However, some other studies 
found a modest inverse association between 2576GG 
polymorphism and homocysteine levels, indicating an 
increased enzymatic activity of the variant genotype 
[12]. For the MTRR, the most common polymorphism 
is an isoleucine-to-methionine change at position 22 
A66G (A66G; rs1801394), and it has demonstrated that 
66GG genotype was inversely associated with plasma 
homocysteine levels [13].  
 
 
 
 
 
 
Figure 1. Schematic presentation of the folate, methionine, and homocysteine metabolism. DHF, dihydrotetrafolic acid; THF, tetrahy-
drofolic acid; 5,10-MTHF, 5,10-methylenetetrahydrofolate; 5-MTHF, 5-methyltetrahydrofolat; SAM, S- adenosylmethionine; MTHFR, 
methylenetetrahydrofolate reductase; MTR, methionine synthase; MTRR, methione synthase reductase. 
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Considering  the  functional  effects  of  the  poly-
morphisms of these enzymes, it is expected that these 
gene polymorphisms may be associated with the CRC 
risks,  and  thus  a  large  number  of  epidemiological 
studies  have  been  conducted  trying  to  clarify  the 
above  question,  but  obtain  conflicting  results.  For 
example,  some  studies  show  a  protective  effect  of 
677TT  variant  against  CRC  [4,  14, 15],  while  others 
found  no  association  and  even  deleterious  effects 
[16-18]. Similarly, the association between the other 
three gene polymorphisms and the risk of CRC also 
remains controversial. Race, life style, and the pattern 
of diet may have introduced variability into the test of 
genetic susceptibility to disease in the different stud-
ies [19]. To clarify these issues, we performed a me-
ta-analysis from all eligible studies, in order to pro-
vide more accurate estimate of the association of the 
above four gene polymorphisms and the risk of CRC. 
Materials and methods 
Literature and search strategy  
A computerized literature search was conducted 
for the relevant available studies published in English 
from 3 databases including PubMed (1950 to 2012), ISI 
web of science (1975 to 2012), and Embase (1966 to 
2012).  The  search  strategy  to  identify  all  possible 
studies involved use of the combinations of the fol-
lowing  key  words:  (“one-carbon  metabolism”  or 
“methylenetetrahydrofolate reductase” or “MTHFR” 
or  “methionine  synthase”  or  “MTR”  or  “methione 
synthase reductase” or “MTRR”) and (“colorectal” or 
“colon” or “rectal”) and (“cancer” or “carcinoma” or 
“adenocarcinoma”). The reference lists of review arti-
cles,  clinical  trials,  and  meta-analyses,  were  also 
hand-searched  for  the  collection  of  other  relevant 
studies. If more than one article were published using 
the same case series, only the study with largest sam-
ple size was selected. The literature search was up-
dated on Feb 28, 2012. 
Inclusion criteria  
The  studies  included  must  meet  the  following 
criteria:  (1)  evaluating  the  association  between 
MTHFR C677T or MTHFR A1289C or MTRR A66G or 
MTR A2756G polymorphism and the risk of CRC; (2) 
case-control or cohort design; (3) providing sufficient 
data for calculation of odds ratio (OR) with the cor-
responding  95%  confidence  interval  (95%CI).  When 
genotype frequencies and OR with 95%CI were all not 
available, authors were contacted to request the rele-
vant information. All identified studies were carefully 
reviewed independently by two investigators to de-
termine whether an individual study was eligible for 
inclusion in this meta-analysis 
Data extraction 
Data  were  extracted  independently  by  two  in-
vestigators  who  reached  a  consensus  on  all  of  the 
items. The following information was extracted from 
each study: (1) name of the first author; (2) year of 
publication; (3) country of origin; (4) ethnicity of the 
study  population;  (5)  source  of  control  subjects;  (6) 
numbers  of  cases  and  controls;  and  (7)  numbers  of 
genotypes in cases and controls. 
Statistical analysis 
We use χ2 analysis with exact probability to test 
departure from Hardy-Weinberg equilibrium (HWE) 
for the genotype distribution. The association of four 
gene polymorphisms with CRC risk was estimated by 
calculating pooled ORs and 95% CI. The significance 
of the pooled effect size was determined by  Z test. 
Heterogeneity among studies was assessed using Q 
test as well as the I2 statistic, which was documented 
for  the  percentage  of  the  observed  between-study 
variability  due  to  heterogeneity  rather  than  chance 
[20]. The DerSimonian and Laird random effect model 
(REM) was used as the pooling method when I2 > 50%, 
otherwise,  the  Mantel-Haenszel  fixed  effect  model 
(FEM)  was  considered  to  be  the  appropriate  choice 
[20].  Subgroup  analysis  stratified  by  ethnicity  was 
only considered for Asians and Caucasians as small 
numbers  of  studies  were  conducted  in  other  ethnic 
groups. Cumulative meta-analysis was performed to 
assess whether the combined estimate changed in the 
same direction over time [21]. Influential analysis was 
undertaken  by  removing  an  individual  study  each 
time to check whether any of single study could bias 
the  overall  estimate  [22].  An  individual  study  was 
suspected of excessive influence, if the point estimate 
of its omitted analysis lies outside of the 95%CI of the 
combined  analysis.  Begg’s  funnel  plots  and  Egger’s 
regression test were undertaken to assess the potential 
publication  bias  [23].  Probability  less  than  0.05  was 
judged  significant  except  for  the  I2  statistic.  Data 
analysis  was  performed  using  STATA  version  11 
(StataCorp LP, College Station, Texas, USA). 
Results 
Characteristics of studies  
A total of 41 (17,552 cases and 26,238 controls), 
24(8,263 cases and 12,033 controls), 12(3,758 cases and 
5,646 controls), and 13 (5,511 cases and 7,265 controls) 
studies were finally included in the meta-analyses for 
the association between the MTHFR C677T, MTHFR 
A1298C, MTRR A66G, MTR A2756G and the risk of Int. J. Biol. Sci. 2012, 8 
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CRC, respectively. Among these studies, Keku et al. 
provided  data  on  two  ethnicities  [24],  while  Le 
Marchand  et al.  reported  on  three  separate  popula-
tions[25], and thus each subpopulation in these two 
studies  were  treated  as  a  separate  one.  All  the  in-
cluded studies used blood samples for the extraction 
of  DNA,  except  for  the  study  by  Shannon  et al.  in 
which frozen tissues samples were used [26]. Geno-
typing was performed by using PCR-RFLP, real-time 
PCR, or Taqman SNP genotyping assay. These studies 
were performed in a wide range of geographical set-
tings leading to a diversity of racial groups. For the 
MTHFR  C677T,  20  studies  recruited  Caucasians  [4, 
14-16, 18, 24-38]; 11 studies examined individuals of 
Asian  descent  [25,  39-48];  the  remaining  10  studies 
were on Indians, Africans, Hawaiian, or mixed pop-
ulation. For the MTHFR A1298C, MTRR A66G, MTR 
A2756G analyses, 12, 6, and 7 studies were conducted 
in Caucasians, respectively, while 5, 3, and 3 studies 
were in Asians. Genotype distributions in the controls 
of all studies were in HWE except for 8 studies for 
MTHFR  C677T  polymorphism  [29,  31,  37,  40,  44, 
48-50], 4 studies for A1298C polymorphism [14, 17, 28, 
41], 1 study for MTRR A66G polymorphism [47], and 
1  study  for  MTR  A2756G  polymorphism  [17].  The 
detailed characteristics of the included studies were 
shown in the supplementary Table 1. 
Quantitative data synthesis 
Results  of  pooled  analysis  on  the  associations 
between  MTHFR  C677T,  MTHFR  A1298C,  MTRR 
A66G, MTR A2756G polymorphisms and the risk of 
CRC  were  shown  in  Table  1-3,  respectively.  There 
was evidence that the T allele of MTHFR C677T re-
sulted in decreased susceptibility to CRC in a world-
wide population (OR = 0.93, 95%CI 0.90-0.96), as well 
as in Asians (OR = 0.89, 95%CI 0.84-0.94) and Cauca-
sians (OR = 0.92, 95%CI 0.88-0.97). Mild to moderate 
between-study  heterogeneity  was  found  (I2  <50%). 
Significant associations were also found in the geno-
types  contrasts  in  homozygous  comparison  (TT  vs. 
CC:  OR  =  0.83,  95%CI  0.77-0.88),  in  the  recessive 
model (TT vs. TC+CC: OR = 0.84, 95%CI 0.79-0.89), 
and in the dominant model (TT+TC vs. CC: OR = 0.95, 
95%CI 0.91-0.99), except for the comparison of CT vs. 
CC  (OR  =  0.98,  95%CI  0.94-1.02)  in  the  worldwide 
populations  (Table  1).  The  sub-group  analysis  by 
ethnicity  also  revealed  significant  association  in 
Asians  and  Caucasians  in  the  above  genotype  con-
trasts except for the homozygous contrast in Cauca-
sians. (TT vs. CC, OR = 0.85, 95%CI 0.72-1.01) (Fig.2). 
Sensitivity  analysis  was  performed  by  excluding  8 
studies deviated from HWE [29, 31, 37, 40, 44, 48-50]; 
however,  the  results  were  not  materially  altered  in 
either genetic model (Table 1). 
In contrast to the significant association between 
MTHFR  C677T  and  the  risk  of  CRC,  the  MTHFR 
A1298C polymorphism was found to be not signifi-
cantly related with the risk of CRC. As shown in Ta-
ble 2, a marginal association was found in the allele 
comparison (G vs. A: OR = 0.96, 95%CI =0.91-1.00, P = 
0.50), and in the homozygous genotypes comparison 
(GG vs. AA: OR = 0.86, 95%CI = 0.78-0.96), and in the 
recessive model (GG vs. GA+AA: OR = 0.86, 95%CI = 
0.78-0.95). The pooled results  were not significantly 
changed  after  exclusion  of  studies  deviated  from 
HWE in every contrast (Table 2). However, when we 
further excluded the studies by Wang et al. and Keku 
et al., in which the 95%CI did not overlap the lines of 
the pooling results, the significant associations were 
all disappeared (G vs. A: OR = 0.97, 95%CI =0.93-1.02; 
GG  vs.  AA:  OR  =  0.92,  95%CI  =  0.82-1.03;  GG  vs. 
GA+AA: OR = 0.91, 95%CI = 0.81-1.01).  
This  meta-analysis  also  provided  supporting 
evidence  for  the  association  of  MTRR  A66G  poly-
morphism and CRC risk. As shown in Table 3, G al-
lele of MTRR A66G resulted in increased susceptibil-
ity  to  CRC  in  a  worldwide  population  (OR  =  1.11, 
95%CI 1.01-1.18), as well as in Caucasians (OR = 1.09, 
95%CI 1.01-1.16), but not in Asians (OR = 1.12, 95%CI 
0.95-1.32).  No  between-study  heterogeneity  was 
found in these comparison (I2 =0.0%). Regarding the 
genotypes,  there  was  also  significant  association  in 
homozygous contrast (GG vs. AA) in the worldwide 
populations (OR = 1.24, 95%CI 1.09-1.40) as well as in 
the Caucasians (OR = 1.18, 95%CI 1.03-1.36), but not in 
Asians (OR = 1.40, 95%CI 0.71-2.77) (Fig.3). However, 
no  significant  association  was  found  in  Asians  or 
Caucasians  in  other  genetic  comparisons  (Table  3). 
Furthermore, the pooled results were not significantly 
altered after excluding one study by Mastuo et al. [47], 
which was deviated form HWE (data was not shown). 
No  significant  association  was  found  for  the 
MTR A2756G polymorphism and the risk of the CRC 
(Table  3).  The  polled  results  were  also  not  signifi-
cantly  altered  after  exclusion  of  the  study  deviated 
from HWE (data was not shown). 
Influence analysis and cumulative analysis  
After excluding studies that deviated from HWE 
in controls, and those in which 95%CI did not overlap 
the lines of the pooling results, no other studies were 
found to significantly influence the pooled effects in 
each genetic model. In the cumulative meta-analysis, 
no particular time trend was found in the summary 
estimate (data was not shown). Int. J. Biol. Sci. 2012, 8 
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Publication bias 
Funnel plots were generated to assess publica-
tion bias. The Egger’s test was performed to statisti-
cally  evaluate  funnel  plot  symmetry.  The  results 
suggested no publication  bias for the association of 
the  MTHFR  C677T,  MTHFR  A1298C,  MTRR  A66G, 
MTR A2756G  polymorphisms  and  the  risk  of  CRC 
(PEgger test = 0.474, 0.922, 0.118, and 0.201, respectively). 
(Fig.4). 
 
Table 1 Ethnicity-stratified pooled measures on the association between MTHFRC677T polymorphism and colorectal 
cancer. 
Contrast  Ethnicity  All relevant articles were included (n = 41)  Articles deviated for HWE were excluded (n=33)a 
OR  95%CI  Statistical 
model 
I2(%)  p value b  OR  95%CI  Statistical 
model 
I2(%)  p value b 
T vs. C  Asian  0.89  (0.84-0.94)**  FEM  47.6%  0.039  0.91  (0.85-0.97)**  FEM  25.2%  0.228 
  Caucasian  0.92  (0.88-0.97)**  FEM  46.4%  0.012  0.93  (0.88-0.97)**  FEM  49.1%  0.012 
  others  0.98  (0.93-1.04)  FEM  5.3%  0.391  0.98  (0.92-1.04)  FEM  17.1%  0.295 
  All  0.93  (0.90-0.96)**  FEM  43.3%  0.002  0.94  (0.91-0.97)**  FEM  38.3%  0.013 
TT vs. CC  Asian  0.76  (0.68-0.86)**  FEM  34.1%  0.126  0.80  (0.70-0.92)**  FEM  29.3%  0.194 
  Caucasian  0.85  (0.72-1.01)  REM  50.8%  0.005  0.86  (0.72-1.03)**  REM  53.1%  0.005 
  Others  0.90  (0.80-1.02)  FEM  25.9%  0.214  0.90  (0.78-1.03)  FEM  35.0%  0.149 
  All  0.83  (0.77-0.88)**  FEM  42.3%  0.003  0.84  (0.78-0.90)**  FEM  42.9%  0.005 
CT vs. CC  Asian  0.94  (0.86-1.02)  FEM  0.0%  0.711  0.95  (0.86-1.04)  FEM  0.0%  0.715 
  Caucasian  0.95  (0.90-1.02)  FEM  39.9%  0.034  0.95  (0.89-1.01)  FEM  46.6%  0.018 
  others  1.04  (0.97-1.13)  FEM  0.0%  0.984  1.03  (0.95-1.12)  FEM  0.0%  0.977 
  All  0.98  (0.94-1.02)  FEM  13.0%  0.241  0.97  (0.93-1.02)  FEM  17.8%  0.186 
TT vs. 
TC+CC 
Asian  0.80  (0.72-0.89)**  FEM  19.5%  0.258  0.83  (0.74-0.94)**  FEM  13.5%  0.325 
  Caucasian  0.84  (0.76-0.93)**  REM  53.7%  0.002  0.89  (0.74-1.06)  REM  56.2%  0.002 
  others  0.88  (0.78-0.99)*  FEM  20.9%  0.257  0.88  (0.78-1.01)  FEM  30.1%  0.188 
  All  0.84  (0.79-0.89)**  FEM  39.8%  0.006  0.85  (0.80-0.91)**  FEM  41.8%  0.007 
TT+CT vs. 
CC 
Asian  0.89  (0.82-0.97)**  FEM  21.2%  0.241  0.91  (0.83-1.00)*  FEM  0.0%  0.446 
  Caucasian  0.93  (0.88-0.99)*  FEM  39.1%  0.039  0.93  (0.87-0.99)*  FEM  44.7%  0.024 
  others  1.02  (0.95-1.09)  FEM  0.0%  0.839  1.01  (0.93-1.09)  FEM  0.0%  0.767 
  All  0.95  (0.91-0.99)**  FEM  27.7%  0.056  0.95  (0.91-0.99)*  FEM  26.3%  0.086 
a 8 studies by Sameer, 2011; by Mohebbi,2008; Zeybek, 2007; Koushik, 2006; Le Marchand, 2005; Jiang, 2005; Park, 1999, and Ma, 1997, were 
excluded as they were deviated from Hardy-Weinberg equilibrium; b p value for heterogeneity based on Q test; FEM, fixed effect model; 
REM, random effect model; *p<0.05; **p<0.01. 
 
Table 2 Ethnicity-stratified pooled measures on the association between MTHFR A1298C polymorphism and colorectal 
cancer. 
Contrast  Ethnicity  All relevant articles were included (n=24)    Articles deviated for HWE were excluded (n=20)a 
OR  95%CI  Statistical 
model 
I2(%)  p value b    OR  95%CI  Statistical 
model 
I2(%)  p value b 
C vs. A  Asian  0.92  (0.80-1.06)  FEM  0.0%  0.680    0.90  (0.77-1.05)  FEM  0.0%  0.678 
  Caucasian  0.99  (0.93-1.05)  FEM  9.6%  0.351    0.99  (0.93-1.05)  FEM  25.9%  0.206 
  others  0.93  (0.86-0.99)*  FEM  48.8%  0.068    0.91  (0.85-0.98)*  FEM  43.1%  0.118 
  All  0.96  (0.91-1.00)*  FEM  18.6%  0.207    0.95  (0.91-0.99)*  FEM  25.4%  0.146 
CC vs. AA  Asian  0.76  (0.49-1.19)  FEM  0.0%  0.488    0.75  (0.44-1.26)  FEM  0.0%  0.871 
  Caucasian  0.93  (0.81-1.07)  FEM  11.3%  0.334    0.93  (0.81-1.08)  FEM  19.9%  0.260 
  others  0.79  (0.67-0.93)**  FEM  12.1%  0.337    0.78  (0.66-0.92)**  FEM  14.4%  0.322 
  All  0.86  (0.78-0.96)**  FEM  0.0%  0.488    0.86  (0.77-0.96)**  FEM  8.6%  0.349 
CA vs. AA  Asian  0.95  (0.80-1.13)  FEM  0.0%  0.470    0.91  (0.75-1.09)  FEM  0.0%  0.618 Int. J. Biol. Sci. 2012, 8 
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Contrast  Ethnicity  All relevant articles were included (n=24)    Articles deviated for HWE were excluded (n=20)a 
OR  95%CI  Statistical 
model 
I2(%)  p value b    OR  95%CI  Statistical 
model 
I2(%)  p value b 
  Caucasian  1.03  (0.95-1.12)  FEM  0.0%  0.610    1.03  (0.94-1.12)  FEM  0.0%  0.567 
  others  0.98  (0.89-1.08)  FEM  23.4%  0.251    0.97  (0.88-1.07)  FEM  7.6%  0.368 
  All  1.00  (0.94-1.06)  FEM  0.0%  0.555    0.99  (0.93-1.06)  FEM  0.0%  0.617 
CC vs. 
CA+AA 
Asian  0.77  (0.49-1.19)  FEM  0.0%  0.953    0.77  (0.46-1.29)  FEM  0.0%  0.878 
  Caucasian  0.91  (0.80-1.04)  FEM  0.0%  0.444    0.92  (0.80-1.06)  FEM  1.2%  0.427 
  others  0.80  (0.68-0.94)**  FEM  0.0%  0.670    0.79  (0.67-0.93)**  FEM  0.0%  0.617 
  All  0.86  (0.78-0.95)**  FEM  0.0%  0.781    0.86  (0.78-0.95)**  FEM  0.0%  0.689 
CC+CA vs. 
AA 
Asian  0.93  (0.79-1.10)  FEM  0.0%  0.533    0.89  (0.74-1.07)  FEM  0.0%  0.622 
  Caucasian  1.01  (0.93-1.09)  FEM  0.0%  0.472    1.01  (0.93-1.10)  FEM  11.2%  0.340 
  others  0.95  (0.86-1.04)  FEM  43.4%  0.101    0.93  (0.85-1.03)  FEM  35.2%  0.173 
  All  0.98  (0.92-1.03)  FEM  10.8%  0.311    0.96  (0.91-1.02)  FEM  13.2%  0.290 
a 4 studies by Guimaraes,2011, Fernandez-Peralta, 2010, Sharp, 2008, and Chang, 2007, were excluded as they were deviated from Har-
dy-Weinberg equilibrium; 
b p value for heterogeneity based on Q test; FEM, fixed effect model; *p<0.05; **p<0.01. 
 
Table 3 Ethnicity-stratified pooled measures on the association between MTRR A66G /MTR A2756G polymorphism and 
colorectal cancer. 
Contrast  Ethnicity   MTRR A66G polymorphism and CRC (n=12)  MTR A2756G polymorphism and CRC (n=13) 
OR  95%CI  Statistical 
model 
I2(%)  p value a  OR  95%CI  Statistical 
model 
I2(%)  p value a 
G vs. A  Asian  1.12  (0.95-1.32)  FEM  0.0%  0.552  1.03  (0.87-1.21)  FEM  0.0%  0.713 
  Caucasian  1.09  (1.01-1.16)*  FEM  0.0%  0.434  0.96  (0.85-1.10)  REM  55.2%  0.037 
  others  1.25  (1.03-1.50)*  FEM  0.0%  0.697  1.19  (0.95-1.48)  FEM  0.0%  0.670 
  All  1.11  (1.04-1.18)**  FEM  0.0%  0.661  0.98  (0.92-1.04)  FEM  36.3%  0.092 
GG vs. AA  Asian  1.40  (0.71-2.77)  REM  58.3%  0.091  1.30  (0.81-2.08)  FEM  0.0%  0.495 
  Caucasian  1.18  (1.03-1.36)*  FEM  23.7%  0.256  0.83  (0.67-1.03)  FEM  48.1%  0.073 
  Others  1.63  (1.08-2.45)*  FEM  0.0%  0.693  1.49  (0.81-2.72)  FEM  0.0%  0.876 
  All  1.24  (1.09-1.40)**  FEM  25.1%  0.197  0.94  (0.78-1.14)  FEM  34.4%  0.107 
GA vs. AA  Asian  1.03  (0.82-1.29)  FEM  0.0%  0.559  0.96  (0.79-1.18)  FEM  0.0%  0.939 
  Caucasian  1.15  (0.93-1.42)  REM  57.6%  0.038  0.97  (0.89-1.06)  FEM  0.0%  0.426 
  Others  1.14  (0.86-1.49)  FEM  0.0%  0.983  1.15  (0.87-1.52)  FEM  0.0%  0.679 
  All  1.09  (0.99-1.21)  FEM  17.5%  0.272  0.98  (0.91-1.06)  FEM  0.0%  0.768 
GG vs. 
GA+AA 
Asian  1.39  (0.64-3.01)  REM  69.7%  0.037  1.32  (0.83-2.10)  FEM  0.0%  0.498 
  Caucasian  1.10  (0.99-1.22)  FEM  0.0%  0.980  0.84  (0.67-1.04)  FEM  39.7%  0.127 
  others  1.56  (1.08-2.25)*  FEM  0.0%  0.651  1.44  (0.79-2.60)  FEM  0.0%  0.883 
  All  1.15  (1.04-1.26)*  FEM  13.0%  0.317  0.95  (0.79-1.14)  FEM  27.3%  0.169 
GG+GA vs. 
AA 
Asian  1.09  (0.88-1.34)  FEM  0.0%  0.981  0.99  (0.82-1.21)  FEM  0.0%  0.868 
  Caucasian  1.17  (0.96-1.42)  REM  55.2%  0.048  0.96  (0.88-1.04)  FEM  37.4%  0.143 
  others  1.23  (0.95-1.59)  FEM  0.0%  0.917  1.19  (0.91-1.56)  FEM  0.0%  0.680 
  All  1.14  (1.03-1.25)*  FEM  7.4%  0.373  0.98  (0.91-1.05)  FEM  8.1%  0.365 
a p value for heterogeneity based on Q test; FEM, fixed effect model. REM, random effect model; *p<0.05; **p<0.01. 
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Figure 2. Meta-analysis for MTHFR C677T polymorphism and CRC in Caucasian, Asian, and the worldwide population (TT vs. CC). Each 
study was shown by a point estimate of the effect size (OR) (size inversely proportional to its variance) and its 95% confidence interval 
(95%CI) (horizontal lines). The whit diamond denotes the pooled OR. 
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Figure 3. Meta-analysis for MTRR A66G polymorphism and CRC in Caucasian, Asian, and the worldwide population (GG vs. AA). Each 
study was shown by a point estimate of the effect size (OR) (size inversely proportional to its variance) and its 95% confidence interval 
(95%CI) (horizontal lines). The whit diamond denotes the pooled OR. 
 
Figure 4. Begg’s funnel plot with the Egger’s test for publication bias of MTHFR C677T and A1289C, MTRR A66G, MTR A2756G pol-
ymorphism and the risk of CRC. The horizontal line in the funnel plot indicates the fixed-effects summary estimate, whereas the diagonal 
lines pseudo-95% CI limits about the effect estimate. In the absence of publication bias, studies will be distributed symmetrically above and 
below the horizontal line. Int. J. Biol. Sci. 2012, 8 
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Discussion  
CRC  is  the  third  most  common  cause  of  can-
cer-related  mortality  in  the  western  world,  and  it 
represents the second most common cause of cancer 
death in the United States [51]. The incidence of CRC 
varies  substantially  worldwide,  with  high  rates  in 
western countries and low rates in African and Asian 
countries in general [52].  Over the past decades, the 
roles of folate and genetic polymorphisms of enzymes 
involved in folate metabolism have attracted consid-
erable  interest  in  epidemiological  research  on  this 
cancer  type.  Among  these  enzymes,  MTHFR,  MTR, 
and MTRR, are the three mostly investigated ones in 
the literature. Unfortunately, conflicting results were 
obtained ranging from strong links to no association. 
The  divergent  results  regarding  the  effects  of  these 
genetic  polymorphisms  upon  CRC  risk  may  be  at-
tributed to the differences in racial origin of the pop-
ulation, the lifestyle, and the pattern of diet in distinct 
countries [17]. Because of the above-mentioned con-
flicting  results  from  relatively  small  studies  under-
powered to detect the effects, a meta-analysis should 
be an appropriate approach to obtain a more defini-
tive conclusion.  
In the current study, we examined the associa-
tion of MTHFR C677T and A1298C, MTRR A66G, and 
MTR A2756G polymorphisms with the susceptibility 
to CRC, with a total of 41, 24, 12, and 13 studies in-
cluded, respectively. The data clearly showed that the 
T allele of C677T polymorphism in MTHFR gene was 
significantly  associated  with  reduced  risk  of  CRC, 
while the G allele of A66G polymorphism in MTRR 
gene might be significantly associated with increased 
risk of CRC (Table 1 and 3). The sub-group analysis 
by  ethnicity  revealed  that  homozygosity  for  the  T 
allele  (MTHFR  677TT  genotype)  is  associated  with 
significantly reduced risk of CRC in Asians and Cau-
casians, while the MTR 66GG genotype was found to 
be significantly increased the risk of CRC in Cauca-
sians but not in Asians. However, no significant asso-
ciation was found between the MTHFR A1298C and 
MTR A2756G  polymorphisms  and  the  risk  of  CRC 
(Table 2 and 3). Although a marginal association was 
found in the allele and genotypes contrasts of MTHFR 
A1298C (C vs. A, CC vs. AA, and CC vs. CA+AA), the 
signification  was  all  disappeared  after  exclusion  of 
one study, in which the 95%CI did not overlap the 
lines  of  the  pooled  results.  After  excluding  studies 
that  deviated  from  HWE  in  controls,  and  those  in 
which 95%CI did not overlap the lines of the pooling 
results, no other studies were found to significantly 
influence  the  pooled  effects  in  each  genetic  model. 
Cumulative meta-analysis showed no particular time 
trend existed in the summary estimate. Furthermore, 
no potential publication bias was detected by funnel 
plots and Egger’s regression test. These data indicated 
the  robustness  of  the  summary  estimate  deserved 
from this study.  
To  the  best  of  our  knowledge,  this  is  the  first 
meta-analysis addressing the associations between the 
four  common  polymorphisms  of  three  critical  en-
zymes involved in folate metabolism and the risk of 
CRC in one study. From 2005 to now, a total of 5 me-
ta-analyses  about  the  association  between  MTHFR 
C677T  and  the  risk  of  CRC  have  been  conducted 
[52-56]. The most recently one conducted by Taioli et 
al. included 29 studies; 28 of those were included in 
our meta-analysis, which also included an additional 
11  studies  primarily  published  between  2008  and 
2012. The pooled results of the current meta-analysis 
were similar to those by Taioli et al. The pooled OR for 
genotype  TT  (vs.  CC)  was  0.83  (95%CI:  0.77,  0.90), 
while  those  were  0.83  (95%CI:  0.74,  0.94)  and  0.80 
(95%CI: 0.67, 0.96) in Caucasians and Asians, respec-
tively  [53].  Similarly,  the  pooled  ORs  in  our  study 
were 0.83(95%CI: 0.77, 0.88), 0.85 (95%CI: 0.72, 1.01), 
and  0.76  (95%CI:  0.68,  0.86),  respectively.  The  me-
ta-analysis  conducted  by  Huang  et  al.  included  14 
studies for the analysis of the association of MTHFR 
A1298C and the risk of CRC [55]. They found that a 
significantly decreased risk of CRC for 1298C poly-
morphism in a recessive genetic model in worldwide 
populations (OR = 0.81, 95%CI 0.70-0.94) and Cauca-
sians (OR = 0.75, 95%CI 0.57-0.99). However, although 
a  marginal  association  was  found  in  the  allele  and 
genotypes contrast of MTHFR A1298C (C vs. A, CC 
vs.  AA,  and  CC  vs.  CA+AA),  the  signification  all 
disappeared after exclusion of the study by Wang et 
al. and Keku et al. [24, 57], in which the 95%CI did not 
overlap the lines of the pooled results (G vs. A: OR = 
0.97, 95%CI =0.93-1.02; GG vs. AA: OR = 0.92, 95%CI 
=  0.82-1.03;  GG  vs.  GA+AA:  OR  =  0.91,  95%CI  = 
0.81-1.01). The discrepancy between our study and the 
study by Huang et al. might be explained by the addi-
tion of 12 studies and the different methodology of the 
two studies by Wang et al. and Keku et al. [24, 57]. This 
meta-analysis also provided supporting evidence for 
the association of MTRR A66G polymorphism and the 
risk of CRC. G allele of MTRR A66G resulted in in-
creased susceptibility to CRC in a worldwide popula-
tion (OR = 1.11, 95%CI 1.01-1.18), as well as in Cauca-
sians (OR = 1.09, 95%CI 1.01-1.16), but not in Asians 
(OR = 1.12, 95%CI 0.95-1.32). In contrast, no signifi-
cant  association  was  found  for  the  MTR  A2756G 
polymorphism and the risk of CRC.  
Reasons for the conflicting results obtained from 
different  studies  about  the  association  between  the Int. J. Biol. Sci. 2012, 8 
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polymorphisms  of  the  three  investigated  genes  in-
volved in folate metabolism and the risk of CRC may 
be attributed to the genetic heterogeneity in different 
populations and the clinical heterogeneity in different 
studies. CRC is well-known as a multifaceted disorder 
influenced by both genetic and environmental factors. 
The differences in age, gender, and lifestyle may lead 
to different results. In the current meta-analysis, most 
of the studies enrolled subjects of both gender, while 
some others investigated the association in male pa-
tients [37]. In addition, several studies have demon-
strated  the  associations  between  genotypes  MTHFR 
677CT+TT and MTR 2756AG+GG genotypes with an 
early disease onset (<50 years of age)  [17, 19]. Fur-
thermore, folate deficiency which was seen in many 
studies, might also affect the activity of enzymes in-
volved  in  DNA  synthesis,  methylation,  and  repair 
pathways,  leading  to  the  hypomethylation  of  DNA 
and the activation of proto-oncogene, as well as the 
inducing  uracil  misincorporation  during  DNA  syn-
thesis, which may also contribute to the discrepancy 
of different studies [58]. In fact, the study by Chen et 
al.  have  suggested  that  dietary  methyl  supply  was 
particularly critical among patients with MTHFR CC 
genotypes, which may be at a reduced risk of CRC 
probably as higher levels of 5,10-MTHF may prevent 
imbalances of nucleotide pools during DNA synthesis 
[38]. Moreover, the association of alcohol consump-
tion with CRC risk has been related to its anti-folate 
effects and subsequent effects on  DNA methylation 
[59].  Thus,  age,  gender,  and  diet  particularly  folate 
and alcohol intake, may modify the effects of these 
gene polymorphisms and the risk of CRC. 
Despite the clear strengths of our study such as 
the larger sample size comparing with the previous 
individual ones, however, it does have some limita-
tions. First, the present meta-analysis was based pri-
marily on unadjusted effect estimates and CIs (since 
most  studies  did  not  provide  the  adjusted  OR  and 
95%CI controlling for potential confounding factors), 
so  the  effect  estimates  were  relatively  imprecise.  If 
individual data were available, adjusted Ors could be 
obtained to give a more precise analysis. Second, the 
effects  of  gene-gene  and  gene-environment  interac-
tions were not addressed in this meta-analysis, and 
thus the potential roles of the above gene polymor-
phism  may  be  masked  or  magnified  by  other 
gene-gene/gene-environment  interactions.  Thirdly, 
we  did  not  perform  stratification  analysis  by  age, 
gender,  drinking  status,  serum  folate  levels,  etc, 
which  might  induce  confounding  bias.  Finally,  alt-
hough  the  funnel  plot  and  Egger’s  test  showed  no 
publication bias, selection bias may also exist because 
only published studies were retrieved.  
In summary, the current meta-analysis system-
atically analyzed the association between the risk of 
CRC and four common polymorphisms of three im-
portant genes involved in folate metabolism. The data 
showed that MTHFR 677T allele might provide pro-
tection against CRC in worldwide populations, while 
MTRR 66G allele might increase the risk of CRC in 
Caucasians  but  not  in  Asians.  In  contrast,  MTHFR 
A1298C and  MTR A2756G polymorphism were un-
likely to be related with the risk of CRC. Since poten-
tial confounders could not be ruled out completely in 
this  meta-analysis,  further  studies  were  needed  to 
confirm these results. 
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